Sydney Lupkin
-
The $1.6 billion Novavax contract is one of several Operation Warp Speed agreements issued through a third party, Advanced Technology International, and that hadn't been released.
-
Newly released COVID-19 vaccine contracts include weakened protections against potential price gouging. Several key federal contracts still haven't been disclosed by the government.
-
To boost the supply of Regeneron's antibody therapy for COVID-19, the federal government entered into a $450 million supply contract. Details of the deal show some safeguards are missing.
-
Drug industry veteran Moncef Slaoui is a key figure in Operation Warp Speed's push to develop COVID-19 coronavirus vaccines. His employment terms raised concerns about potential conflicts of interest.
-
Most of the federal contracts with companies involved in the crash program to make COVID-19 vaccines haven't been made public. The lack of disclosure raises questions about accountability.
-
A panel of doctor and scientists raised questions about the expedited regulatory path the Food and Drug Administration is considering for COVID-19 vaccines.
-
Members of Congress and advocacy groups say Operation Warp Speed should release its contracts with vaccine makers after NPR reporting found the terms of many aren't public.
-
The requirements laid out by the Food and Drug Administration in advice for drugmakers underscore why it's unlikely a vaccine could clear the agency before Election Day.
-
More than $6 billion in federal funding has been routed through a firm that manages defense contracts, making the agreements subject to less federal scrutiny and transparency.
-
Health policy researchers say Trump may not be able to pay for the cards, which fall short of lasting policy changes to curb high drug prices.